iTeos Therapeutics (NASDAQ:ITOS) Receives Outperform Rating from Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They presently have a $25.00 price objective on the stock. Wedbush’s target price points to a potential upside of 244.35% from the stock’s current price.

A number of other research firms have also recently issued reports on ITOS. Wells Fargo & Company cut their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, January 16th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS traded up $0.41 during mid-day trading on Wednesday, hitting $7.26. 463,605 shares of the stock traded hands, compared to its average volume of 447,781. iTeos Therapeutics has a twelve month low of $6.67 and a twelve month high of $18.75. The firm has a 50 day simple moving average of $7.54 and a two-hundred day simple moving average of $9.57. The company has a market cap of $265.24 million, a PE ratio of -2.30 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. On average, equities research analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Algert Global LLC raised its stake in shares of iTeos Therapeutics by 92.0% during the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after purchasing an additional 122,730 shares during the period. State Street Corp grew its stake in iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after buying an additional 211,452 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after buying an additional 5,368 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in iTeos Therapeutics by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock valued at $2,268,000 after purchasing an additional 8,397 shares in the last quarter. Finally, Readystate Asset Management LP boosted its stake in shares of iTeos Therapeutics by 97.2% in the 3rd quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock valued at $1,734,000 after purchasing an additional 83,700 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.